Clinical benefit of gemcitabine plus cisplatin 3-week regimen for patients with advanced non-small-cell lung cancer (NSCLC): a prospective observational study / 中国癌症杂志
China Oncology
;
(12)2000.
Article
in Chinese
| WPRIM
| ID: wpr-540555
ABSTRACT
Purpose:
To study the effectiveness and safety o f first-line chemotherapy with GEM-Cis 3-week regimen in routine care of Chin ese patients with advanced NSCLC.Methods:
Gem-Cis 3-week regimen was used as first line chemoth erapy to treat stage Ⅲb/Ⅳ NSCLC patients, measurements of effectiveness includ ed clinical benefit and significant clinical response (SCR), and side events of GEM-Cis in the treatment of stage Ⅲb/IV NSCLC.Results:
221 patients with cytological or pathological confirmed stage Ⅲb or IV NSCLC were enrolled, 209 eligible for effectiveness and safety analysis. Median age 58 years (range, 29 to 79 years); males females, 67.5%∶ 32.5%; stage Ⅳ ⅢB, 52.5%∶47.8 %; KPS
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Observational study
Language:
Chinese
Journal:
China Oncology
Year:
2000
Type:
Article
Similar
MEDLINE
...
LILACS
LIS